HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could keep BRCA breast cancer from coming back
Disease control OngoingThis study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control OngoingThis study tests two drugs, olaparib and pembrolizumab, given before standard surgery for people with triple-negative or hormone receptor-positive HER2-negative breast cancer who have specific gene mutations. The goal is to see if the combination can shrink tumors enough to impro…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a drug combo keep High-Risk breast cancer from coming back?
Disease control OngoingThis phase 3 trial tested whether adding the drug everolimus to standard hormone therapy helps prevent breast cancer from returning in nearly 2,000 patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. Participants received either hormone therapy plus e…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo shows promise in slowing breast cancer growth
Disease control OngoingThis phase 3 trial tests whether adding abemaciclib to standard hormone therapy (anastrozole or letrozole) can slow cancer growth in postmenopausal women with HR+ HER2- breast cancer that has spread or returned. About 493 women participated, receiving either the drug combination …
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Two-Drug cocktail shows promise for tough cancers
Disease control OngoingThis early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC